Penicillium marneffei is an opportunistic human pathogen endemic to Southeast Asia. At 25° P. marneffei grows in a filamentous hyphal form and can undergo asexual development (conidiation) to produce spores (conidia), the infectious agent. At 37° P. marneffei grows in the pathogenic yeast cell form that replicates by fission. Switching between these growth forms, known as dimorphic switching, is dependent on temperature. To understand the process of dimorphic switching and the physiological capacity of the different cell types, two microarray-based profiling experiments covering approximately 42% of the genome were performed. The first experiment compared cells from the hyphal, yeast, and conidiation phases to identify "phase or cell-state-specific" gene expression. The second experiment examined gene expression during the dimorphic switch from one morphological state to another. The data identified a variety of differentially expressed genes that have been organized into metabolic clusters based on predicted function and expression patterns. In particular, C-14 sterol reductase-encoding gene ergM of the ergosterol biosynthesis pathway showed high-level expression throughout yeast morphogenesis compared to hyphal. Deletion of ergM resulted in severe growth defects with increased sensitivity to azole-type antifungal agents but not amphotericin B. The data defined gene classes based on spatio-temporal expression such as those expressed early in the dimorphic switch but not in the terminal cell types and those expressed late. Such classifications have been helpful in linking a given gene of interest to its expression pattern throughout the P. marneffei dimorphic life cycle and its likely role in pathogenicity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815061 | PMC |
http://dx.doi.org/10.1534/g3.113.006809 | DOI Listing |
BMC Infect Dis
December 2024
Central Laboratory, Chongqing Public Health Medical Centre, Chongqing, China.
Background: In acquired immunodeficiency syndrome patients, Talaromyces marneffei infections are mostly disseminated and may involve the skin, mucosa, respiratory system, digestive system, lymphatic system, and as some reports indicate, the nervous system. Mp1p, a cell wall-specific polysaccharide in Talaromyces marneffei, is used for laboratory diagnosis of Talaromyces marneffei in blood and urine samples. However, Cerebrospinal fluid Mp1p diagnosis of Talaromyces marneffei central nervous system infection has not been reported.
View Article and Find Full Text PDFMycopathologia
December 2024
Clinical Laboratory, Department of Clinical Laboratory, The People's Hospital of Longhua Shenzhen, Shenzhen, 518109, People's Republic of China.
J Appl Microbiol
December 2024
Institute of Marine Drugs, Faculty of Pharmacy, Guangxi University of Chinese Medicine, No.13 Wuhe Road, Nanning 530200, China.
Aims: The present study aims to investigate the in vitro antifungal activity and mechanism of action of bamemacrolactine C (BAC), a new 24-membered macrolide compound, against Talaromyces marneffei.
Methods And Results: The test drug BAC initially demonstrated antifungal activity through a paper disk diffusion assay, followed by determination of the minimum inhibitory concentration value of 35.29 μg ml-1 using microdilution.
Int J Infect Dis
February 2025
College of Public Hygiene of Guangxi Medical University, Nanning, Guangxi, China.
Objectives: This systematic review and meta-analysis aimed to evaluate the prevalence of bone destruction in patients with Talaromyces marneffei infection, examine distribution patterns of bone lesions, and assess differences between HIV-positive and HIV-negative patients.
Methods: Following PRISMA guidelines, 15 studies involving 839 patients were analyzed. Random-effects meta-analysis was performed to estimate prevalence and odds ratios.
Zhonghua Jie He He Hu Xi Za Zhi
December 2024
Department of Respiratory and Critical Care Medicine, Fuzhou Provincial Hospital Affiliated to Fuzhou University, Fuzhou350001, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!